Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07443215 · ClinicalTrials.gov registry record · NA
Evaluation of Effect of Scatter on Visual Performance
A NA study of Visual Acuity, sponsored by Johnson & Johnson Vision Care.
- Recruiting
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT07443215: Recruiting NA study of Visual Acuity, sponsored by Johnson & Johnson Vision Care.
NCT07443215 is a NA study of Visual Acuity that is actively recruiting participants, run by Johnson & Johnson Vision Care. The registered enrollment target is 36 participants, below the 138-participant average among 20 other Visual Acuity trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07443215, a NA study of Visual Acuity, is actively recruiting participants, sponsored by Johnson & Johnson Vision Care.
- RECRUITING
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a 3-visit, single-site, randomized, single-masked, bilateral wear, non-dispensing, crossover study which will evaluate visual performance with different magnitudes of scatter.
Primary Outcome
Distance (4 meters) Monocular High luminance high contrast (HLHC) logMAR Visual acuity (VA) without glare will be assessed after lens fitting.
Conditions Studied
Interventions
- DEVICE ACUVUE® OASYS 1-Day Sphere
- DEVICE ACUVUE® OASYS Multifocal
Study Locations (1)
Florida
- VRC - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-02-13 |
| Est. Completion | 2026-05-08 |
| Phase | NA |
What NCT07443215 shows while recruiting
NCT07443215 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 138-participant average among 20 other Visual Acuity trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Visual Acuity appearing as the primary indexed condition, and to 2 interventions - of which ACUVUE® OASYS 1-Day Sphere is the first listed.
NCT07443215 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07443215 about?
NCT07443215 is a clinical study titled "Evaluation of Effect of Scatter on Visual Performance". This will be a 3-visit, single-site, randomized, single-masked, bilateral wear, non-dispensing, crossover study which will evaluate visual performance with different magnitudes of scatter.
What is the current status of trial NCT07443215?
This trial is currently recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2026-02-13. Estimated completion is 2026-05-08.
What conditions does trial NCT07443215 study?
This clinical trial studies the following conditions: Visual Acuity.
What interventions are being tested in trial NCT07443215?
The interventions under investigation include: ACUVUE® OASYS 1-Day Sphere (DEVICE), ACUVUE® OASYS Multifocal (DEVICE).
Who is sponsoring clinical trial NCT07443215?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07443215 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Visual Acuity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07443215's enrollment target sits among peer trials
36 19th of 20 higher than 2 of 20 other Visual Acuity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Visual Acuity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population Phase 2
COMPLETED · NA
-
Evaluation of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses
COMPLETED · NA
-
Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses
COMPLETED · NA
-
Clinical Evaluation of Approved Contact Lenses
COMPLETED · NA
-
Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL
COMPLETED · NA
-
Clinical Evaluation of Manufacturing Processes for a Reusable Multifocal Optical Design in a Presbyopic Population
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI